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Liposomal formulations were signiﬁcantly explored over the last decade for the ophthalmic drug delivery applications. These
formulations are mainly composed of phosphatidylcholine (PC) and other constituents such as cholesterol and lipid-conjugated
hydrophilic polymers. Liposomes are biodegradable and biocompatible in nature. Current approaches for topical delivery of
liposomes are focused on improving the corneal adhesion and permeation by incorporating various bioadhesive and penetration
enhancing polymers. In the case of posterior segment disorders improvement in intravitreal half life and targeted drug delivery
to the retina is achieved by liposomes. In this paper we have attempted to summarize the applications of liposomes in the ﬁeld of
ophthalmicdrug delivery by citing numerous investigators over the last decade.
1.Introduction
Ocular drug delivery is challenging in terms of achieving
optimum drug concentration due to unique protective
mechanisms of the eye. Development of a drug delivery
system for attaining therapeutic concentration at the target
site requires a comprehensive understanding of static and
dynamic barriers of the eye. The eye has two broadly
deﬁned segments, (a) anterior segment, and (b) posterior
segment. Anterior segment is the front one-third of the
eye that includes the optical structure in front of vitreous
humor: cornea, pupil, aqueous humor, iris, lens and ciliary
body. Posterior segment is the back two-thirds of the
eye that mainly includes sclera, choroid, retina, vitreous
humor, macula, and optical nerve. The common routes
of drug administration for the treatment of eye disorders
are topical, systemic, periocular, and intravitreal. Topical
administration isthemost preferred routebecause ofhighest
patient compliance and least invasive nature. Upon topical
instillation, absorption of drugs takes place either through
corneal route (cornea, aqueous humor, intraocular tissues)
or noncorneal route (conjunctiva, sclera, choroid/RPE). The
cornea can be mainly divided into the epithelium, stroma
and endothelium, where each layer oﬀers a diﬀerent polarity
and a potential rate-limiting structure for drug permeation.
The non-corneal route involves absorption across the sclera
and conjunctiva into the intraocular tissues. However,
a small fraction of the topically applied drugs, generally less
than 5%, reaches the intraocular tissues. Factors responsible
for poor ocular bioavailability following topical instillation
are precorneal drainage and lipoidal nature of the corneal
epithelium. In addition, a major fraction of drug reaches
the systemic circulation through conjunctival vessels and
nasolacrimal duct, which leads to severe adverse eﬀects.
Consequently, topical route has met with limited success in
attaining therapeutic drug concentrations in the posterior
segment. Systemic administration can provide therapeutic
levels in the posterior segment, but administration of high
doses is necessary, which often leads to severe side eﬀects.
Blood-aqueous barrier and blood-retinal barrier are the
two major barriers for anterior segment and posterior
segment ocular drug delivery, respectively, after systemic
administration. Thetightjunctionalcomplexeslocatedinthe
two discrete cell layers, the endothelium of the iris/ciliary
blood vessels, and the nonpigmented ciliary epithelium oﬀer
blood-aqueous barrier which prevents the entry of solutes
into the aqueous humor. Blood retinal barrier is composed
of two types of cells, that is, retinal capillary endothelial cells
and retinal pigment epithelium (RPE) cells which prevents
theentry ofsoluteinto theretina. Intravitreal administration2 Journal of Drug Delivery
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requires frequent administration which may lead to high
susceptibility for vitreous hemorrhage, retinal detachment
and endophthalmitis. These side eﬀects can be minimized
by developing delivery systems which provide controlled
and targeted drug delivery for prolonged periods [1–3].
Conventional ophthalmic formulations such as solutions
and suspensions exhibit poor bioavailability. Over the last
decade, numerous drug delivery systems have been explored
to overcome the limitation of conventional dosage forms.
Novel formulations such as nanoparticles, liposomes, den-
drimers, and niosomes were developed to enhance drug
bioavailability and to minimize adverse eﬀects[4, 5]. Among
themliposomalformulationswerewidelyexploredinthelast
decade for drug delivery applications.
In 1965 liposomes were ﬁrst introduced as the drug
delivery carriers [6]. Liposomes are usually within the size
rangeof10nmto1μmorgreater.These vesicularsystems are
composed ofaqueouscore enclosedby phospholipid bilayers
of natural or synthetic origin. Liposomes are structurally
classiﬁed onthebasis of lipidbilayerssuch as small unilamel-
lar vesicles (SUVs) or multilamellar vesicles (MLVs). Fur-
thermore, on the basis of size, liposomes are classiﬁed into
small unilamellar vesicles (SUVs), giant unilamellar vesicles
(GUVs), and large unilamellar vesicles (LUVs) (Figure 1).
Unilamellarvesiclesarecomposedofsinglelayeroflipidsuch
as lecithin or phosphatidylglycerol encapsulating aqueous
interior core. Multilamellar vesicle is composed of various
layers of lipid bilayers [7–9]. MLVs are metastable energy
conﬁguration having diﬀerent facets depending upon the
polydispersity ofthe liposomal formulation. Various typesof
liposomes with size are summarized in Table 1.
Drug loading capacity of liposomes depends on many
factors such as size of liposomes, types of lipid utilized
for preparation, and physicochemical properties of ther-
apeutic agent itself. For example, being the smallest in
size entrapping eﬃc i e n c yf o rS U V si sp o o ri nc o m p a r i s o n
to MLVs. However, LUVs provide a balance between size
and drug loading capacity. Liposomes are advantageous in
Table 1: Size of diﬀerent types of liposomes [12].
Vesicle type Size
SUVs ∼20nm to ∼200nm
LUVs ∼200nm to ∼1μm
MLVs >0.5μm
GUVs >1μm
encapsulating both lipophilic and hydrophilic molecules.
Hydrophilic drugs are entrapped in the aqueous layer, while
hydrophobic drugs are stuck in the lipid bilayers. Loading
capacity ofionic moleculescan be further improved by using
cationic or anionic lipids for the preparation of liposomes
[11].
Majority of liposomal formulations utilize phosphatidyl-
choline (PC) and other constituents such as cholesterol and
lipid-conjugated hydrophilic polymers as the main ingre-
dients. Incorporation of cholesterol enhances the stability
by improving the rigidity of the membrane. Stability of
liposomes depends upon the various properties such as
surface charge, size, surface hydration, and ﬂuidity of lipid
bilayers. Surface charge determines interaction of liposomes
with ocular membrane. Positively charged liposomes display
better corneal permeation than the neutral and nega-
tively charged liposomes. Neutral liposomes upon systemic
administration evade the elimination by reticuloendothelial
system (RES). However, these vesicles possess higher self-
aggregation tendency. In contrast, negatively and positively
charged liposomes exhibit lower aggregation tendency but
undergo rapid clearance by RES cells due to higher interac-
tion with serum proteins. In addition, size of the liposomes
can also regulate the clearance by RES. Liposomes of size less
than 100nm generallyexhibitsigniﬁcantly higher circulation
time due to decrease in opsonization of liposomes with
serum protein [13].
Amphiphilic nature of phospholipids allows these
molecules to form lipid bilayers. This unique feature is
utilized for the preparation of liposomes. In general, hydra-
tion of phospholipids results in the formation of MLVs,
which can be processed into SUVs with proper sonication.
However, addition of aqueous solution of surfactant above
the critical micelle concentration results in the formation
of phospholipids micelles. After the dialysis of surfactant
aggregation of micelles form LUVs, critical micelle concen-
trations of amphiphiles which can form micelles are four
to ﬁve orders of magnitude higher than the phospholipids
which form liposomes [12]. Numerous methods have been
reported to prepare liposomes. Most commonly solvent
evaporation method, reverse phase evaporation method and
detergent dialysis method are employed [14]. The encap-
sulated drug from liposome can be released either through
passive diﬀusion, vesicle erosion, or vesicle retention. In
passive diﬀusion, drug molecules tend to penetrate through
the lipid layers of liposome to reach extra vesicular layer
either by diﬀusion or convection mechanism. The rate of
diﬀusion depends on the size, lipid composition, and the
properties of the drug itself [15–17]. Unilamellar liposomes
exhibit faster release rate than multilamellar ones becauseJournal of Drug Delivery 3
in multilayered liposome, drug diﬀusion occurs through
a series of barriers; hence, the drug release is delayed.
Phospholipase and high-density lipoproteinpresent in blood
plasma can damage phospholipid layers of liposome and
thus results in vesicle erosion and releases the encapsulated
drug into the cell. The drug release rate depends on the
extent of liposomal membrane damage [18]. Liposome-
cell interactions depend on several factors like size, surface
charge, composition of liposomes, targeting ligand on the
surface of liposome, and biological environment. Lipo-
somes can interact with cells by four diﬀerent mechanisms:
adsorption, fusion, lipid exchange and endocytosis (receptor
mediated). Liposomes can be speciﬁcally or nonspeciﬁcally
adsorbed onto the cell surface or can be fused with cell
membranes, and release encapsulated drug inside the cell.
During adsorption, liposomes can release encapsulated drug
in front of cell membrane, and released drug can enter cell
via micropinocytosis. They can also be engulfed inside the
cellby speciﬁc ornonspeciﬁc endocytosisprocess. Negatively
charged liposomes have been found to be more eﬃcient
than neutral liposomes for internalization into the cells
by endocytosis process. Liposomes bind to the receptor
present in the invaginations of cellular membrane and are
internalized into the cell by endocytotic pathway. After
endocytosis, they can fuse with the endosomal membrane
to form endosome which can be delivered to lysosomes. In
lysosomes, the presence of peptidase and hydrolase degrades
the liposomes and their content. To avoid this degradation
and thus to increase cytoplasmic bioavailability, stimuli-
responsive liposomes (such as pH or temperature) have
been developed. pH-sensitive liposomes can undergo fusion
with endosomal membrane and release their content directly
into cytosol. In some cases liposomes become destabilized
inside the endosome and release their content, or they
destabilize endosomal membrane resulting in leakage of
encapsulated content into cytosol [19, 20]. In this paper we
haveattemptedtosummarize theapplicationofliposomes in
theﬁeldofophthalmicdrugdeliveryattemptedbynumerous
investigators over the last decade.
2.ApplicationofLiposomesin
OphthalmicDrug Delivery
Liposomes have been investigated for ophthalmic drug
delivery since it oﬀers advantages as a carrier system.
It is a biodegradable and biocompatible nanocarrier. It
can enhance the permeation of poorly absorbed drug
molecules by binding to the corneal surface and improving
residence time. It can encapsulate both the hydrophilic
and hydrophobic drug molecules. In addition, liposomes
can improve pharmacokinetic proﬁle, enhance therapeutic
eﬀect, and reduce toxicity associated with higher dose.
Owing to their versatile nature, liposomes have been widely
investigated for the treatment of both anterior and pos-
terior segment eye disorders. Current approaches for the
anterior segment drug delivery are focused on improving
corneal adhesion and permeation by incorporating various
bioadhesive and penetration enhancing polymers. However,
in the case of posterior segment disorders, improvement of
intravitreal half-life and targeted drug delivery to the retina
is necessary. Currently verteporﬁn is being used clinically
in photodynamic therapy for the treatment of subfoveal
choroidal neovascularization (CNV), ocular histoplasmosis,
or pathological myopia eﬀectively. Verteporﬁn is a light-
activated drug which is administered by intravenous infu-
sion. In photodynamic therapy, after the drug is injected,
a low-energy laser is applied to the retina through the
contact lens in order to activate verteporﬁn that results
in closure of the abnormal blood vessels. Unfortunately,
photodynamic therapy usually does not permanently close
the abnormal vessels and choroidal neovessels reappear after
several months. Another liposomal photosensitizing agent,
rostaporﬁn, was evaluated for the treatment of age-related
macular degeneration. It is now under phase 3 clinical trial.
Rostaporﬁn requires less frequent administration compared
to verteporﬁn. Liposome technology has been explored
for ophthalmic drug delivery. However, there are some
issues to be addressed such as formulation, and storage of
l i p o s o m e si sv e ryd i ﬃcult,and they are known to cause long-
term side eﬀects. Intravitreal administration of liposomes
has resulted in vitreal condensation, vitreal bodies in the
lower part of eye, and retinal abnormalities. Therefore, all
these factors should be taken into account while developing
liposomal formulation for ophthalmic application [21–25].
Recent applications of liposomal formulations encapsulating
various therapeutic molecules are summarized in Table 2.
3.TopicalApplications
In 1981, Samolin et al. investigated the role of liposomes
in ophthalmic drug delivery. Since then several investigators
proposed strategies to enhance absorption of drugs having
poor physicochemical properties. Studies performed by
Schaeﬀer and Krohn suggested the role of charge and size
in transcorneal permeation. Investigators observed four-
fold higher in vitro corneal ﬂux from penicillin G-loaded
SUVs. They reported corneal permeation in the order of
SUV+ > MLV− > SUV− > SUV > MLV free drug. These
studies explored the role of vesicle type on transcorneal per-
meationacrosstheexcisedrabbitcornea[36].Roleofphysic-
ochemical property of entrapped drug was elucidated by
other investigators. Liposomal formulation of TA produced
twofold increase in drug concentration in both the cornea
and aqueous humor in the rabbit model. On the contrary,
liposomal formulation of hydrophilic drug, that is, dihy-
drostreptomycin sulfate, did not improve the corneal per-
meation [37, 38]. Considering these ﬁndings, it was evident
that both vesicle type and physicochemical property of drug
signiﬁcantly aﬀects the transcorneal ﬂux of the formulation.
Earlier investigation by Fitzgerald et al. was signiﬁcant
in exploring the clearance of liposomes by gamma scintig-
raphy following topical administration in the rabbit model.
These investigators reported, SUVs with positive charge had
improvedthecornealretentionbyinteractingwithnegatively
charged corneal surface. Since then, approaches based on
positively charged liposomes were explored considerably.
Researchers also explored immunoliposomes, lectin func-
tionalized liposomes, and positively charged lipid analogs.4 Journal of Drug Delivery
Table 2: Application of liposomes for the delivery of various drug molecules.
Drug Formulation Result Year Ref
GCV Liposomes
In vitro transcorneal
permeation and in vivo
ocular pharmacokinetics
was improved
2007 [26]
Ciproﬂoxacin Liposomal
hydrogel
Fivefold higher
transcorneal permeation
than the liposomes alone
2010 [27]
Levoﬂoxacin
Liposomes
attached to
the contact
lens
Drug was released
following ﬁrst-order
kinetics for more than 6
days and formulationhad
showed activity against S.
aureus.
2007 [28]
Herpes
simplex virus
antigens
Periocular
vaccine
Treated rabbits showed
anti-gB immune response
and protected against
reactivation of HSV
infection
2006 [29]
Acetazolamide
Neutral- and
surface-
charged
liposomes
Positively charged
liposomes reduced IOP and
exhibited prolonged eﬀect
than negatively charged
liposomes
2007 [30]
Tacrolimus Liposomes
More than 50ng/mL
vitreous concentration was
maintained for 2 weeks and
reduced drug related
toxicity
2010 [31]
Vasoactive
intestinal
peptide
Rhodamine-
conjugated
liposomes
Liposomes were
internalized by retinal
M¨ uller glial cells, resident
macrophages;majority of
the liposomes reached the
cervical lymph nodes and
resulted in slower release
and long-term expression
inside the eye
2007 [32]
Clodronate Liposomes
Eﬀectively inhibit
inﬁltration of ED2-positive
macrophages
2005 [33]
Plasmid DNA Cationic
liposomes
Signiﬁcantlyincreased
transfection eﬃciency of
pDNA
2004 [34]
Therapeutic
DNA
Cationic
lipoplexes
Achieved good vitreous
mobility with moderately
pegylated cationic
lipoplexes with size less
than 500nm
2005 [35]
Among these approaches only immunoliposomes did not
improved liposome-corneal interaction. However, lectin and
lipid analog-based approaches are not explored considerably
in the ﬁeld of ophthalmic drug delivery [39].
Approach of utilizing chitosan in the formulation was
reported to be advantageous in improving the precorneal
residence time due to its mucoadhesive nature. Degrada-
tion of chitosan into oligosaccharides is mediated through
lysozymes, and degradation products are nontoxic in nature
[40, 41]. Biodegradable nature is advantageous for selecting
chitosan in the formulation of ocular drug delivery sys-
tems. Topical administration of chitosan-coated liposomes
(chitosomes) improves precorneal retention and also slows
down drug metabolism at the precorneal epithelial surface.
Chitosan-based mucoadhesive liposomal formulation of
CPX was prepared and evaluated by Mehanna et al. ReverseJournal of Drug Delivery 5
phase evaporation technique was utilized for the preparation
of liposomes, which were further coated with chitosan
of diﬀerent molecular weights. The authors reported that
liposomes coated with high molecular weight chitosan were
smallerinsize duetocompletecoverageofliposomalsurface,
which acted as a physical barrier to inhibit aggregation. In
addition, authors determined lower encapsulation eﬃciency
(EE) of 49.93% for coated liposomes in comparison to
uncoated negative and neutral liposomes with 71.4% and
53.2%EE,respectively,duetoelectrostaticrepulsionbetween
chitosan and cationic drug. The eﬀect of liposomal surface
charge on the particle size was also determined. Negatively
charged liposomes were larger in diameter due to predomi-
nantly electrostatic attraction between the positively charged
chitosan and negatively charged phospholipids. Rheological
studies revealed ideal pseudoelastic behavior of chitosomes
and higher apparent viscosity than the liposome dispersion.
The author suggested that pseudoelastic property of chito-
some provides prolonged retention and stability of tear ﬁlm.
Moreover, in vitro release studies with chitosomes exhibited
slower drug release rate in comparison to free liposomes due
to additional diﬀusion barrier for drug molecule. Ex vivo
cornealpermeationstudiesacross isolated rabbitcorneasug-
gested that due to absorption enhancing nature of chitosan
relative permeability of chitosomes was 1.74-fold higher
than free drug. Furthermore, in vitro antibacterial studies
revealed that chitosomes exhibited enhanced antibacterial
activitythanthemarketedaqueoussolutionagainstreference
and clinically isolated strains of Pseudomonas aeruginosa and
Staphylococcus aureus. Authors suggested the electrostatic
interaction of positively charged chitosan and negatively
charged bacterial cell wall enhanced the antibacterial action
of liposomal formulation. Comparative single dose in vivo
study performed on bacterial conjunctivitis rabbit model
revealed that chitosomes inhibited the growth of Pseu-
domonas aeruginosa for 24h. It was reported that marketed
product(Clioxan)iscomparatively lesseﬀectiveand requires
frequent administration. These investigators demonstrated
the role of medium molecular weight chitosan. However,
other studies suggest the advantages of water-soluble low
molecular weight chitosan as potential biopolymer for
coating liposomes [42]. Application of LCH was advanta-
geous in eliminating the aggregation behavior of chitosan
at physiological pH that had dramatically inﬂuenced in
vivo performance of the liposomal formulation. Investigator
reported higher ex vivo corneal penetration across excised
rabbit cornea in the case of LCH-coated liposomes as shown
in Figure 2. However, higher concentration of LCH (0.25%
and 0.5% w/w) did not show signiﬁcant change in particle
size. Researchers suggested that a loose coating layer is
responsible for aggregation of vesicles which resulted in
higher particle size in the case of 0.1% w/v LCH. Moreover,
the drug release at 6h was 38.9% in noncoated liposomes
whereas only 25.4% drug release was observed in liposomes
coated with 0.25% w/v chitosan solution. Both nontreated
and treated group did not demonstrate any abnormality of
the corneal and conjunctival epithelial cells. In addition, no
ocular irritation and inﬂammatory response was observed.
In vitro precorneal retention studies in rabbits showed that
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Figure 2: Corneal penetration proﬁles of diclofenac sodium in
diﬀerent vehicles, noncoated liposome (Non-L), LCHL2 (0.25%
Low molecular weight chitosan, w/v), and LCHL3 (0.5% low
molecular weight chitosan, w/v), (with permission from [10])
the elimination of chitosan-coated liposomes was slower
than non-coated liposomes. Authors suggested that mucin
ﬁlm, which primarily covers the surface of cornea and
conjunctiva, is composed of negatively charged glycoprotein.
Electrostatic alteration between positively charged LCH and
mucin promotes prolonged retention. In addition, hydrogen
bonding interactions of LCH with the ocular surface also
favorsprecornealretention.Thisstudydemonstratedtherole
of LCH in improving the precorneal retention. However,
previousstudies with high molecular weight chitosan-coated
liposomes did not improve the precorneal retention due
to enhanced intramolecular interactions. Histopathological
analysis of the LCH-coated liposomes in rabbits after long-
term irritation test revealed that the formulation was bio-
compatible with the ocular tissues (Figure 3)[ 10].
Application of quaternized derivatives of chitosan that
is, N-trimethyl chitosan chloride (TMC), with signiﬁcantly
higher water solubility at physiological pH, was evaluated
forsurfacemodiﬁcationofcoenzymeQ10-loadedliposomes.
Improved stability of the modiﬁed liposomes was reported.
In addition, surface modiﬁcation with cationic polymeric
ﬁlm reduced particle aggregation through stearic stabi-
lization and improved precorneal retention than uncoated
liposomes due to ionic interaction with negatively charged
corneal surface. Investigators reported almost 4.8-fold
increase in precorneal residence time measured by gamma
scintigraphy after administration of 25μL of formulation.
Histological analysis and draize test performed on rabbits
revealed that TMC was biocompatible with corneal epithe-
lium. Moreover, higher molecular weight TMC exhibited
better anticataract activity in Sprague Dawley rats [43].
To take the dual advantage of chitosan-based nanoparticles
and liposomes, Diebold et al. prepared liposome-chitosan
nanoparticle complexes [44]. As mentioned earlier, chitosan
nanocarriers were employed in topical drug delivery because6 Journal of Drug Delivery
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Figure 3: Histopathology microscopy of the ocular tissues after being treated with LCHL for 7 days. cornea of nontreated (a), treated with
LCHL2 (b), and LCHL3 (c); conjunctiva of nontreated (d), treated with LCHL2 (e) and LCHL3 (f) (with permission from [10]).
of its mucoadhesive nature, whereas liposomes can incor-
porate variety of drug molecules and improve ocular drug
bioavailability [45–47]. These nanosystems were formulated
as eye drops, which possessed combined properties of
both carriers and overcome the ocular mucosal barriers.
These authors evaluated the nanosystems for toxicity on
spontaneously immortalized epithelial cell line from nor-
mal human conjunctiva (IOBA-NHC). Cells pre incubated
with XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxyalinide) solution (1mg/mL XTT in
100mL of phenol red-free RPMI culture medium) were
exposed todiﬀerentconcentrationsofchitosan nanoparticles
and liposome-chitosan nanoparticles complexes. Cytotoxic-
ity was determined by measuring the production of yellow
colordueto cleavageofXTT by mitochondrial enzymes. Cell
viability after exposure of liposome-chitosan nanoparticle
complexes was higher in comparison to chitosan nanoparti-
cles alone. They also performed in vivo acute tolerance test
by administrating the formulations topically to the female
albino New Zealand rabbits. The nanosystems did not show
any evidence of toxicity to the both sham-controlled and
treated eyes. No sign of irritation on ocular surface was
conﬁrmed by clinical microscopic sign score. Also, in vivo
experiments have shown that nanosystems can enter the
conjunctival cells without causing histological alteration to
the cornea, conjunctiva, and lid tissues in the rabbit model.
In addition, the complexes did not release any inﬂammatory
mediators in cornea, conjunctiva, and eyelids [44].
Vaccination approach can successfully overcome the
limitations of antiviral agents in the treatment of HSV
infections. However, delivery of vaccines is the major
hurdle facing by pharmaceutical scientists. Administration
by conventional parenteral route has several drawbacks
such as high cost, need of highly trained personnel, and
needle-stick injuries. Cationic liposomes containing herpes
simplex virus (HSV) antigens were proposed as potential
carriers, in the form of a periocular vaccine, to protect
animals against subsequent HSV-1 ocular challenges. Two
diﬀerent peptides, namely, DTK1 and DTK2 (DTKs), having
antiherpetic activity were synthesized. Cationic liposomes
containing both DTK and secretory HSV-1 glycoprotein B
were formulated. Liposomal formulation showed eﬀective
results in a rabbit model of HSV-1 infection [29].
Zhang et al. utilized cytochrome-C (Cyt-C) loaded
cationic liposomes for the treatment of selenite-induced
cataract in rats. These liposomes were fabricated by thin-
layer evaporation technique. Authors investigated the eﬀect
of composition on the encapsulation eﬃciency. This study
reported improvement in the entrapment eﬃciency (EE)
with increasing phosphatidylcholine component, whereas
EE was lowered by incorporating stearylamine. Cyt-C
loaded freeze-dried liposomes were stable for one year at
4◦C. Furthermore, these liposomes exhibited remarkable
eﬃcacy (28% decrease in lens opacity) in minimizing
the cataract formation. Liposomal encapsulation of Cyt-
C has signiﬁcance, but the preparation method adapted
by these authors was similar to previous investigations
[48].
In another study, ﬂuconazole liposomal formulation was
evaluated in the candidal keratitis model in rabbits. In
this investigation, comparative eﬃcacy of the ﬂuconazole
solution and ﬂuconazole-loaded liposomes was determined.
The purpose of developing liposomal formulation was to
prolong the antifungal action by increasing the contact
time. In the rabbits treated with ﬂuconazole solution, 50%
healing was observed in 3 weeks, whereas 86.4% healing was
observed in rabbits treated with ﬂuconazole encapsulated
liposomes. Authors attributed enhanced pharmacological
activity tohigherviscosity and lipidsolubilityofﬂuconazole-
loaded liposomes [49].Journal of Drug Delivery 7
C h r o n i co c u l a ri n f e c t i o u sd i s e a s e ss u c ha sc o n j u n c t i v i t i s ,
bacterial keratitis need high drug concentration at the site
of infection. Treatment of these diseases requires frequent
eye drop administrations that may cause drug resistance
and also decrease patient compliance. In order to minimize
precorneal drainage and increase bioavailability viscosity
enhancers such as poly (vinyl alcohol) and polymethacrylic
acid were blended with eye drop solution [50]. Many investi-
gators evaluated the role of liposomal hydrogel formulation
for the delivery of ﬂuoroquinolone antibiotics. For example,
liposomal hydrogel formulation of ciproﬂoxacin (CPX)
was reported to avoid tear-driven dilution in the cul de
sac. Lecithin (LEC)and α-L-dipalmitoylphosphatidylcholine
(DPPC)were utilizedasmajor ingredientsinthepreparation
of multilamellar liposomes. Poly (vinyl alcohol) (PVA)
and polymethacrylic acid (PMA) derivatives were utilized
for gel formulation. Various formulation parameters such
as viscosity and rheological property of liposomes was
evaluatedin relation to the in vitro release [51]. CPX because
of its negative charge electrostatically interacts with lipid
head group of the phospholipid bilayers [52]. Therefore,
majority ofdrugwas entrappedinside the liposomes. Similar
electrostatic interaction between lipid bilayers and other
ﬂuoroquinolones such as oﬂoxacin and lomeﬂoxacin were
reported in other studies [53]. The investigator observed
that use of viscosity enhancing agents in the formulation
had aﬀected the drug release rate. The addition of gel
forming agents PVA and PMA did not aﬀect the rigidity of
liposomal membrane, instead these polymers were adsorbed
on the surface of multilamellar liposomal surface because
of method of formulation. Hydration of lipids with proper
concentration of PVA and PMA results in the formation of
polymerlayeronthesurface oftheliposomes[54,55].Direct
correlation was observed between viscosity of hydrogel and
drug release rate. In addition, they found a remarkable
diﬀerence in drug release half-time between two diﬀerent
lipids, that is, LEC and DPPC. The presence of unsaturated
lipid in LEC provides less rigid structure to the liposome
formulation that resulted in faster drug release in com-
parison to DPPC. Hydrogel formulation has shown plastic
properties; that is, under higher shear stress condition, it
remained in free ﬂowing state, whereas it exhibited no ﬂow
state at rest. Overall, the use of optimized formulation of
liposomal hydrogel can sustain the release of antibacterial
agents in comparison to liposomes alone, and this approach
could be beneﬁcial in the treatment of various chronic
ocular infectious diseases. In another study, CPX-loaded
liposomal hydrogel formulation improved transcorneal per-
meation in rabbit model. Liposomes were suspended in the
hydrogelmatrixcomposedofcarbopol940.Theinvestigators
reported that drug entrapment eﬃciency was enhanced with
the increase of cholesterol concentrations, which provided
higher stability and lower permeability of lipid bilayers.
Furthermore, higher encapsulation eﬃciency with positively
charged liposomes was observed due to favorable electro-
static attraction between CPX and cationic stearylamine.
Liposomes of higher size were obtained upon incorporation
of charge inducing agents, which expand lipid bilayers dis-
tance. Positively charged liposomes exhibited slower release
rate,andCPXreleasewasmoresustainedfromtheliposomes
suspended in the carbopol gel because of additional barriers
for diﬀusion. Liposomal hydrogel displayed ﬁvefold higher
in vitro transcorneal permeation across excised rabbitcornea
than the aqueous solution. This approach was already
explored by other investigators. Although authors observed
enhanced in vitro transcorneal permeation, it would be
interesting to evaluate these formulations for in vivo studies,
where tear dilution plays a major role [27]. In a similar study
by these researchers, transcorneal permeation of oﬂoxacin-
loaded thermosensitive liposomal hydrogel was evaluated.
Two diﬀerent types of liposomes, MLV and reverse phase
evaporationvesicles(REV),wereprepared.Authorsobserved
smaller particle size with REV relative to MLV due to
diﬀerences in the method of preparation. Splicing of the
lipid monolayer in a more curved structure resulted in
REV of smaller diameter. Authors evaluated chitosan/β glyc-
erophosphate thermosensitiveh y d r o g e ls y s t e m .I n c o r p o r a -
tion of liposomes in thermosensitive gels reduced the gelling
time from 5 to 1 minute. The researchers suggested that
hydrophobic interaction can reduce energy requirement for
gelation.Transcornealpermeationstudiesacrossexcisedrab-
bit cornea revealed sevenfold higher drug permeation from
the liposomal formulation than oﬂoxacin aqueous solution.
This eﬀect was observed due to mucoadhesive nature of the
hydrogel base which prolonged the retention of formulation
across the excised rabbit cornea. In addition, cationic nature
of chitosan in the thermogelling system promoted corneal
adherence and opened corneal epithelial tight junctions.
Researchers concluded that oﬂoxacin liposomal formulation
will reduce the formation of crystalline deposit and also
frequency of administration. Another investigation suggests
threefold increase in corneal residence of ophthalmic for-
mulation containing chitosan. The ocular irritation test
suggests excellent tolerance of chitosan formulation evalu-
ated with confocal laser scanning ophthalmoscope [56, 57].
A liposomal spray formulation was recently evaluated for
changes in preocular tear ﬁlm. After application of the spray,
liposomes traverse to the tear ﬁlm. Liposomal formulation
was evaluated on human subjects, and eﬀectiveness was
compared to normal saline at diﬀerent time points. Authors
reported statistically signiﬁcant improvement in tear ﬁlm
stability and lipid layer stability in comparison to control.
These studies suggest the potential of liposomal sprays in the
treatment of dry eye syndrome [58].
Liposomes were also investigated for the topical deliv-
ery of intraocular pressure (IOP) lowering agents. For
example, acetazolamide was encapsulated in liposomes to
enhance the solubility and corneal permeation. Liposomes
were formulated by reversed phase evaporation and liquid
hydration methods with and without the use of positive
or negative charge inducers to prepare REV and MLV.
Liposomes of diﬀerent compositions were evaluated for
entrapment eﬃciency, stability, in vitro release, and IOP
lowering eﬃcacy in rabbit model. The entrapment eﬃciency
of acetazolamide was found highest with positively charged
liposomes followed by neutral and negatively charged lipo-
somes because ofionic interaction between anionic drugand
lipid bilayers. Cationic and neutral MLVs of acetazolamide8 Journal of Drug Delivery
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Figure 4: In vitro transcorneal permeation of GCV liposomes and
solution(with permissionfrom [26]).
exhibited maximum eﬀectiveness in terms of release proﬁle
forthesamereason[30].AnotherIOPreducingagent,deme-
clocycline (DEM), was encapsulated in liposomes which
enhanced ocular permeability. This formulation achieved
long-lasting IOP lowering eﬀects relative to pilocarpine
liquid formulation [59]. Monem et al. reported pilocarpine
HCl loaded liposomes which were administered topically.
This studyreported twodiﬀerentliposomeswith neutraland
negatively charged multilamellar surface. Neutral liposomes
were more eﬀective in IOP lowering eﬀect than negatively
charged liposomes or free drug. In addition, phase transition
and size distribution studies showed long term stability (15
months) of the liposomal formulation [60].
Liposomal formulations were also developed for the
delivery of antiviral agents. Shen and Tu reported the appli-
cation of liposomes for the delivery of ganciclovir (GCV)
to the vitreous humor via topical administration in the
rabbits. GCV liposomes were prepared by the reversed phase
evaporation method utilizing PC/CH/sodium deoxycholate
mixture. In vitro transcorneal permeability and in vivo
ocular pharmacokinetics of the liposomal formulation were
compared with the GCVsolution. Transcorneal permeability
was 3.9-fold higher (Figure 4), and ocular bioavailability
of GCV liposomes was 1.7-fold greater in comparison to
solution (Figure 5). GCV concentrations from liposomal
formulation were 2 to 10 times higher in various ocular
tissues. In addition, in vivo experiments suggested that
the scleral pathway contributed in the absorption of GCV
liposomes,asthehighest concentrationofGCVwas obtained
in the sclera. Concentrations of GCV attained in the cornea
and the sclera were higher than IC50 value of GCV against
CMV. The author suggested that the particle size (i.e.,
200nm) and composition of the liposomes played a major
role in transocular permeation [26].
Disposable contact lenses presoaked with medication
solution have been utilized for continuous drug delivery.
However, in presoaked contact lenses, drug molecules ran-
domly disperse within the contact lenses and show burst
release that can cause local tissue toxicity or other side
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Figure 5: Concentration-time proﬁle of GCV in aqueous humor
after instillation of 1mg/mL GCV liposome preparation and GCV
solutionin rabbits (with permissionfrom [26]).
eﬀects [61]. To avoid rapid drug release and to provide site-
speciﬁc delivery, another novel strategy, liposomes loaded
soft contact lenses, was proposed for the antibiotics in
the treatment of ocular infections such as bacterial kerati-
tis. Multilamellar liposomal surface of soft contact lenses
was decorated with PEG-Biotin linkage. Contact lenses
withsurface-immobilized levoﬂoxacin-loadedliposomesfol-
lowed ﬁrst-order release kinetics and released the drug over
more than 6 days. In addition, the liposomal formulation
has shown antibacterial activity against S. aureus [28, 62].
In another study, chloramphenicol (CAP) was encapsulated
in dimyristoylphosphatidylcholine (DMPC) liposomes and
formulated in the form of eye drops. Three methods, that
is, CAP-PART (partitioning of CAP in the vesicle bilay-
ers), CAP-EN (entrapment of CAP via normal hydration
method), and CAP-ADS (adsorption of CAP on the vesicle
surface) were employed for the preparation of liposomes.
The formulation was evaluated for interaction of the drug
with the phospholipid bilayers resulting in optimum eﬃcacy
against S. aureus. CAP was localized in the interfacial lipid
bilayers in the case of CAP-EN whereas entrapped deeper in
the bilayers in the case of CAP-PART. These results showed
that CAP located near the interfacial region within the
hydrophobic core of the liposomes had shown highest anti-
bacterial activity against S. aureus for almost 5hrs [63].
Chetoni et al. reported acyclovir (ACV) containing posi-
tively charged unilamellar liposomes (LIPO-ACV), adminis-
tered topically into rabbit eyes. The bioavailability of LIPO-
ACV was compared with free ACV in solution (SOL), ACV
encapsulated in “empty” liposomes (LIPO-EMPTY), and
a diluted dose of commercially available ACV ointment,
containing same ACV concentrations (0.12%). The phar-
macokinetic proﬁle of the drug in the aqueous humor of
rabbits showed highest drug concentration proﬁle for LIPO-
ACV system with 90 minutes plateau. LIPO-ACV exhibited
aqueoushumorACVconcentrationintheupperrangeofthe
ID50 (0.01 to 0.7μg/mL). In a separate study concentratedJournal of Drug Delivery 9
ACV ointment (containing 8-fold greater dose of ACV)
was compared with LIPO-ACV. Only 1.6 times higher
bioavailability was observed with ACV ointment. These
results indicate a signiﬁcant advantage of LIPO-ACV as an
alternative to ACV ointment [47]. In order to give an insight
on release mechanism of ACV from liposomal vehicle, in
vitro release experiments through a cellophane membrane
was performed which showed lower drug release from the
liposomal vehicle through cellophane membrane compared
tothat ofSOLand LIPO-EMPTY. These resultssustained the
conceptthat negatively charged corneal epithelium enhances
the eﬃcacy of positively charged liposomal formulation.
Pleyer et al. formulated diﬀerent cationic liposomes
by changing their lipid compositions in order to improve
gene expressions in corneal endothelial cells. The authors
reported six formulations with diﬀerent cationic lipids
3β[N-(N,N
 -dimethylaminoethane)-carbamoyl] (DAC), di-
carbobenzoxyspermin-carbamoyl (SP), N-Amidino-β-al-
anin-[2-(1,3-dioleoyloxy)propyl]amid-hydrochlorid (DOSGA),
and 1,2-dimyristyloxypropyl-3-methylhydroxethylammoni-
umbromide (DMRIE) which were coupled in varying con-
centrations with neutral lipid dioleoylphosphatidylethanol-
amine (DOPE). Fixed amount of DNA was entrapped in
each liposome which expressed E. coli beta-galactosidase.
Transfection experiments on bovine corneal endothelial cells
(BCEC) indicated that SP20 (SP/DOPE 20/80) generated
highest eﬃciency followed by DMRIE 50 (DMRIE/DOPE
50/50) ranging at approximately 3mU per β-gal per well.
The researchers observed low gene expressions with DAC
30 (DAC/DOPE 30/70), and DOSGA 30 (DOSGA/DOPE
30/70), DOSGA 100 (DOSGA 100) and no gene expressions
for free DNA. At a ﬁxed DNA concentration, the relative
β-galactosidase expressions were decreased with increasing
the cationic lipid dose, which might be due to either toxic
eﬀects of cationic lipids at higher concentrations to the cells
or non-optimal lipid/DNA ratios. The highest eﬃciency
of SP20 liposomes in delivering DNA into BCEC can be
rationalized by consideringitsrapid andstable complexation
with DNA due to result of ionic interactions between the
multivalent lipid and negatively charged phosphate groups
of DNA. SP20 was completely biodegradable compared to
many synthesized lipids as it was derived from naturally
occurring compounds resulting in least toxicity compared to
other liposomal formulations [64].
Teshima et al.studiedprednisolone- (PLS-) incorporated
liposomes to improve retention property of prednisolone.
Introduction of a lipophilic moiety (palmitoyl) to pred-
nisolone (Pal-PLS) greatly enhanced drug retention in
liposomes as lipophilic moiety increased its aﬃnity to lipo-
somal lipid bilayer. The investigators studied two liposomes
containing two diﬀerent lipids, egg phosphatidylcholine
(EggPC) and distearoyl phosphatidylcholine (DSPC). Ultra-
ﬁltration and gel ﬁltration techniques were used to investi-
gate retention properties of PLS and pal-PLS in liposomes.
Whileultraﬁltrationmethodshowedhighincorporationeﬃ-
ciency of PLS into the liposomes, a signiﬁcant decrease of its
incorporation eﬃciency was observed in gel ﬁltration. This
result indicated that elution medium in gel ﬁltration studies
released incorporated PLS from liposomes. Pal-PLS showed
higherincorporationeﬃciencyinbothultraﬁltration andgel
ﬁltration studies. However, incubation of liposomes with rat
plasma for 1min eﬀectivelydecreased Pal-PLS incorporation
into EggPC/Chol liposomes as detected by gel ﬁltration. The
reducing eﬀect of Pal-PLS incorporation into liposomes by
rat-plasma was overcome by using DSPC lipid in liposomal
formulation. Further surface modiﬁcation of liposomes with
a hydrophilic polymer PEG resulted in the protection of
the entrapped palmitoyl-PLS and thus generated a stable
retention property of the drug [65].
Law et al. reported topical administration of acyclovir-
(ACV)- encapsulated liposomes, where in vitro corneal
penetration and in vivo corneal absorption (using male
rabbits) of acyclovirfrom ACV-encapsulated liposomes were
studied. This study reported the eﬀect of liposomal surface
charge on their corneal penetration and absorption. Surface
charge of liposomes plays a signiﬁcant role in improving
the eﬃciency of ocular drug delivery system. Positively
charged liposomes exhibited higher drug loading eﬃciencies
as well as faster drug release rates compared to negatively
charged liposomes. Prolonged penetration across the cornea
was observed for ACV-encapsulated liposomes. This phe-
nomenon was more evident in case of positively charged
liposomes. The penetration rate for positively charged
liposomeswasfoundtobeapproximately3.6-foldlowerthan
free ACV and approximately 2-fold lower than negatively
charged liposomes. Similarly, ACV concentration proﬁle in
aqueous humor indicated higher corneal absorption and
greater corneal deposition of ACV for positively charged
liposomes relative to negatively charged ACV and free ACV.
The researchers suggested that positively charged liposomes
can interact electrostatically with the negatively charged
surface of cornea. This interaction can result in stronger
binding which leads to formation of a completely coated
layer on the corneal surface. This layer may cause an increase
in residence time on the cornea surface resulting in higher
ACV absorption and greater extent of ACV deposition in
the cornea compared to that of negatively charged liposomes
[46].
Kawakami et al. reported O-palmitoyl prodrug of
tilisolol-encapsulated liposome to improve the retention
time of tilisolol in the precorneal area and vitreous body.
The liposomes were administered topically, as well as
intravitreally to the rabbit eye. Following topical adminis-
tration, the researchers observed very low retention of O-
palmitoyl tilisolol in the tear ﬂuid even when it was applied
as liposomal formulation. The investigators signiﬁcantly
increased the retention property of liposomes by adding
2% of carmellose sodium which acted as a reservoir for
liposomes. In caseof intravitreal administration, o-palmitoyl
tilisolol-encapsulated liposomes responded well resulting in
higher drug concentration in the vitreous body compared to
free tilisolol [66].
In the last decade numerous researchers addressed the
challenge of minimizing rapid clearance from precorneal
site and enhancing the corneal permeation through vari-
ous approaches. Utilization of chitosan in the preparation
of mucoadhesive and cationic formulations was widely
explored forthedeliveryofsmall therapeuticmoleculesfrom10 Journal of Drug Delivery
diﬀerent categories. Other mucoadhesive polymers were also
applied in the formulation of hydrogels that can regulate the
drug release rate at the ocular surface.
4.IntravitrealApplications
Liposomes represent the ﬁrst injectable systems for intrav-
itreal administrations. Liposomes can provide sustained
release for prolonged period. In addition, liposomal for-
mulation can minimize the tissue toxicity and enhance the
intravitreal half-life of drugs by decreasing rapid clearance
from vitreous cavity [67, 68].
Barza et al. delineated the eﬀect of liposome size and
pathological state of eye on the intravitreal elimination
kinetics of carriers. Investigators observed that the clearance
rate of SUVs was faster than LUVs. Moreover, intraocular
inﬂammation also increases the intravitreal clearance rate
[69]. Recently ocular pharmacologists have utilized liposo-
mal hydrogel and sterically (pegylated) stabilized liposomes
to address the drawbacks associated with intravitreal admin-
istrations of liposomes [70].
In an application, rhodamine-conjugated liposomes
loaded with vasoactive intestinal peptide (VIP) were given
intravenously to healthy rats to examine eﬃcacy in the treat-
ment of ocular inﬂammation. VIP is an immunomodulatory
neuropeptide involved in the regulation of ocular immune
response by modulating the activities of macrophages, T
lymphocytes, and dendritic cells [19, 71]. Intravitreal appli-
cation of VIP-loaded liposomes was proposed for the treat-
ment of endotoxin-induced uveitis [72]. Internalization of
rhodamine-conjugated liposomes(Rh-Lip)aloneandloaded
with VIP (VIP-Rh-Lip) was examined in male Lewis rats.
Intraocular and systemic biodistributions of the liposomes
were also determined. The authors reported that, after single
intravitreal injection, liposomes were internalized by retinal
M¨ uller glial cells, resident macrophages, and rare inﬁltrating
activated macrophages. Majority of the liposomes reached
the cervical lymph nodes via conjunctival lymphatics. VIP-
Rh-Lip internalized via macrophages resulted in slower
release and long-term expression inside the ocular tissues
and cervical lymph nodes. Thus, intravenous delivery of VIP
by liposomes would be helpful in the treatment of uveitis
and other immune-mediated eye diseases by modulating the
immune microenvironment of the ocular region [32].
Camelo et al. evaluated the liposomal formulation dis-
persed in hyaluronic acid (HA) gel for the delivery of VIP
in the treatment of uveitis and uveoretinitis in Lewis rats.
Major limitation with the VIP-LP was shorter residence time
in the vitreous cavity due to rapid elimination through the
lymphaticcirculation.Investigatorsattemptedtoincreasethe
half-life of VIP-loaded liposomes (VIP-LP) after intravitreal
administration by suspending them in the hydrogel. HA
which is the major component of vitreous was utilized
for the studies. The researchers incorporated liposomes in
HA gel in order to attain sustained release of VIP from
the liposomes. VIP-LP suspended in HA gel was retained
in the vitreous cavity for 8 days after single intravitreal
injection. Authors reported that incorporation of liposomes
in the gel had increased the viscosity of the gel due to
theenhancedinteractionbetweenHAgelandphospholipids.
Moreover, it was reported that formulation was eﬀective
in the treatment as evident by reduced clinical score and
number of polymorphonuclear cells [73].
In a study tacrolimus-loaded liposomes were utilized for
the treatment of uveoretinitis. The vesicles were prepared
by reverse phase evaporation technique and subsequently
evaluated for eﬃcacy and safety following intravitreal injec-
tion in rats. No change in the retinal function was observed
in the liposome-treated rats. Histopathological examination
revealed reduced inﬂammatory response in comparison to
free drug. Liposomes were able to maintain the vitreous
concentrationofmore than50ng/mL for2 weeks aftersingle
administration. Investigators concluded that tacrolimus-
loaded liposomes were more eﬀective than the drug alone.
The formulation also reduced drug-related toxicity to inner
retinal cells [31].
In another study, Abrishami et al. prepared nano-
liposomes of bevacizumab. The investigators utilized
dehydration-rehydration method for achieving highest
encapsulation eﬃciency. Researchers attempted to reduce
the clearance of bevacizumab liposomes by incorporation
of cholesterol. In comparison to free drug, concentration of
liposomal formulation was 5 times higher at 42 days. This
study revealed that liposomal formulation of bevacizumab
was proven eﬀectivein the controlled release of bevacizumab
for more than 6 weeks in rabbit model [74].
Fluconazole liposomes were evaluated for the treatment
of candidal endophthalmitis. In the comparative study,
intravitreal injections of ﬂuconazole solution or liposomal
formulation were given at diﬀerent dose levels in the
rabbit eyes. Administration of ﬂuconazole solution caused
photoreceptor disorientation and ultrastructural changes of
the retina at the concentration of 100μg in 0.1mL or above.
In contrast, liposomal formulation of ﬂuconazole did not
show any retinal alteration up to concentration of 200μgi n
0.1mL [75].
Cheng et al. Formulated lipid prodrug of ganci-
clovir (GCV), 1-O-hexadecylpropanediol-3-phospho-GCV
into liposomes which were injected intravitreally in rabbits.
The researchers used this liposomal formulation for antiviral
treatment against herpes simplex virus type 1 (HSV-1)
and human cytomegalovirus (HCMV). Intravitreal injection
with 0.2nM intravitreal concentrationwas the most eﬀective
without causing any side eﬀects of vitreous clarity or
cataractsdevelopmentinthe eye.Moreover, thisformulation
providedcompleteretinalprotectionevenaftersimultaneous
intravitreal injection [76].
Bochot et al. reported that phosphodiester oligonu-
cleotide encapsulated sterically (pegylated) stabilized lipo-
somes which were administered intravitreally in rabbits.
It was the ﬁrst reported use of liposomes as vehicle for
intravitreal delivery of phosphodiester oligonucleotides. The
investigators tried to overcome the problem of short intrav-
itreal half-life of oligonucleotide by encapsulating [33P]
labeled 16-mer oligothymidylate (PdT16) within liposome.
After intravitreal injection liposomal formulations yielded
signiﬁcantly higherconcentrationofradiolabeled33P within
the posterior segment of the eye (vitreous, retina, choroid,Journal of Drug Delivery 11
and sclera) than the solution. A heterogeneous competi-
tive hybridization assay revealed a signiﬁcantly improved
intraocular stability of PdT16 when it was administered in a
liposomal formulation. The sterically stabilized hydrophilic
polyethylene glycol (PEG) chains on the liposome’s surface
protected them from degradation, resulting in prolonged
residence time in vitreous and sustained release of encap-
sulated oligonucleotide into the vitreous and the retina-
choroid. Controlled release of [33P] PdT16 from liposomes
also inhibited unwanted distribution of oligonucleotide in
thenontargetedtissues(sclera,lens)andthusreducedoverall
ocular toxicity [77].
Peeters et al. reported cationic liposomes as nonviral
gene carriers which were complexed with therapeutic DNA,
called lipoplexes (LPXs). The authors investigated the factors
responsible for ineﬃcient vitreous diﬀusion of nonviral gene
complexes and addressed the problems to overcome vitreous
barrier for lipoplexes. FITC-dextran, ﬂuorescent polystyrene
n a n o s p h e r e sa sm o d e l sf o rL P X sa n dL P X sw e r em i x e dw i t h
vitreous gel obtained from bovine eyes, and their mobility
in vitreous was studied by ﬂuorescence recovery after
photobleaching (FRAP) technique. Polystyrene nanospheres
can bind to collagen ﬁbers within the vitreous due to
hydrophobic interactions resulting in restricted mobility
in the vitreous. To overcome this problem, hydrophilic
polyethylene glycol (PEG) chains were grafted on the surface
of nanoparticles that had prevented adsorption to the colla-
gen ﬁbers and thus increased their mobility in the vitreous.
They reported that the size of the nanospheres should be
less than 500nm to obtain good vitreous mobility; otherwise
it would be sterically hindered by vitreous network and
spread nonhomogeneously throughout the vitreous result-
ing in accumulation near the injection site. Nonpegylated
cationic liposomes aggregated in the vitreous as negatively
charged glycosaminoglycans (GAGs) strongly bind to the
cationic lipoplexes, which neutralize positive zeta potential
of lipoplexes, and thus favor aggregation. Low to moderate
pegylation (1.9mol% DSPE-PEG to 9.1mol% DSPE-PEG)
on cationic lipoplexes prevented their aggregation but,
bindingtobiopolymersinthevitreousstill occurred.Further
increase ofDSPE-PEGto16.7mol% preventedbothvitreous
aggregation as well as binding to vitreous ﬁbrils, resulting
in homogeneous vitreous distribution and vitreous mobility
[35]. The size and zeta potential ofpegylated LPXs decreased
with increasing the amount of pegylated lipids (DSPE-PEG)
inLPXs.GelelectrophoresisexperimentsindicatedthatLPXs
in vitreous remain stable and do not disassemble. The data
on mobility, aggregation, and stability of lipoplexes opened
u pan e wd i r e c t i o nt on o n v i r a lo c u l a rg e n et h e r a p y ,b u t
some factors need to take into consideration. Here transport
of drugs in vitreous was assumed by diﬀusion mechanism
only but in case of larger animal species like humans
drug transport through convection plays a signiﬁcant role.
Moreover here transport was focused in the central parts of
vitreous samples. Cortical vitreous zone containing densely
packed collagen and inner limiting lamina may produce
additional barriers to the diﬀusion of LPXs into the retina.
Gupta et al. evaluated ﬂuconazole-encapsulated lipo-
somes which were administered intravitreally in rabbit
eyes. Entrapping of ﬂuconazole into liposomes signiﬁcantly
slowed down clearance of free ﬂuconazole after intravitreal
injection and thereby achieved higher ﬂuconazole concen-
tration in the vitreous. The liposomes showed longer half-
life (23.40h) in comparison to free ﬂuconazole (3.08h)
[78].Among all these investigations performed by numerous
researchers, approach of entrapping bevacizumab will be
advantageous for designing controlled release system for
therapeutic macromolecules. Another approach of using
sterically stabilized liposomes for oligonucleotide delivery
can be further explored for resolving the challenges in
ocular gene therapy. This approach will be advantageous
in minimizing the intravitreal clearance of liposomes and
distribution of oligonucleotide in the non-targeted tissues.
5.SubconjunctivalApplications
Subconjunctival mode of administration has gained new
momentum in delivering the drugs to both the anterior
and posterior segments [79]. Subconjunctival injection of
liposomes can provide retentive eﬀect and steady-state
release at the site of application. Therefore, higher drug
concentrations can be achieved at the target site. In addi-
tion, subconjunctival injection is better in comparison to
topical application as it can improve patience compliance
by avoiding repeated administrations and provide direct
access of the drug to the target site [80, 81]. Absorption
rate of liposome-bound low molecular weight heparin
(LMWH) was investigated after subconjunctival injection
in the treatment of subconjunctival hemorrhage (SH) in
rabbits. Low concentration of liposome-bound LMWH was
observed as compared to the free LMWH in the intraocular
regions (aqueous and vitreous). Moreover, lower systemic
level of LMWH was noted after subconjunctival injection.
The paper suggested that, due to larger size (approx.
550nm in size), liposomes remained at the site of injection
and avoided lymphatic drainage. Also, positively charged
liposomes encapsulated higher amounts of LMWH and
released the drug in a sustained manner, thus providing
longer residence time and increased concentration at the
targeted site. Thus, subconjunctival application of liposomes
is a possible strategy to avoid systemic side eﬀects of LMWH
[81].Inasimilar study,Baeketal.attemptedsubconjunctival
administration of streptokinase- (SK-) loaded liposomes for
the treatment of SH in rabbits. Freeze thaw method was
utilized for the production of liposomes. The study reported
that 81% of the drug was released in 48h. Higher absorption
eﬃciency of liposomes in comparison to free drug was
observed. SK-encapsulated liposomes in the early phase of
SH need to be assessed [82].
Fukushima et al. reported clodronate liposomes
(CL2MDP-lip), which were used to inhibit inﬁltration of
macrophages in the conjunctiva in the case of blepharo
conjunctivitis (EC) developed in Brown Norway rats.
The liposomes were administered by subconjunctival
injection as well as by intravenous injection. They found
that CL2MDP-lip eﬀectively decreased the number of
ED2-positive macrophages in the conjunctivas, where ED1-
positive macrophages inﬁltration could only be controlled if12 Journal of Drug Delivery
the injection was administered just prior to OVA challenge
[33]. Limited investigations on subconjunctival delivery
of liposomes were performed in the last decade. However,
approach of utilizing liposomes of size greater than 550nm
can be explored in future for long-term delivery by
minimizing the systemic clearance of liposomes through
conjunctival capillaries. It would be interesting to investigate
the subconjunctival clearance of liposomes of various sizes.
6.Conclusion
Numerous applications of liposomes in ophthalmic drug
delivery were extensively studied. These carriers have suc-
cessfully improved the drug bioavailability by controlled and
targeted delivery. In the case of topical application improve-
ment in the precorneal retention, transcorneal permeation,
and therapeutic eﬃcacy was achieved by utilizing liposomal
formulations. In addition, eﬀects of charge and composition
of liposomes were explored in detail, which have provided
comprehensive understanding of the interaction between
liposome and ocular tissues. The applications of chitosan
and hydrogel for improving the precorneal retention of
liposomes were explored and shown potential for further
investigation. Liposomal formulations have been evaluated
for encapsulation of various drug molecules of diﬀerent
therapeutic classes. In particular, liposomal formulation of
small molecules for the treatment of bacterial conjunctivitis
and glaucoma was developed. Moreover, posterior segment
delivery of liposomes was proven successful in enhancing the
intravitreal half-life and targeted delivery to the inner retinal
cells. In the case of posterior segment disorders liposomal
formulation of therapeutic macromolecules was examined.
However, research on targeted delivery of liposomes was
limited. Receptors expressed on the cornea and retina could
be explored in future for targeted drug delivery utilizing
surface-modiﬁed liposomes.
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